Effects Of Benzbromarone And Allopurinol On Inflammatory Factors And Cardiac Function In Patients With Chronic Heart Failure And Hyperuricemia

ObjectiveExploring the effects of allopurinol and benzbromarone on inflammatory factors and cardiac function in patients with chronic heart failure and hyperuricemia.MethodsA total of216patients with chronic heart failure and hyperuricemia (New York Heart Association functional classes II to IV) were randomly selected as study objects during September2011and December2013in Tianjin Chest Hospital. The patients were randomized into three groups:placebo group, benzbromarone group and allopurinol group. Detailed informations were recorded including age, gender, the situation of the heart function and drug history. Blood was taken for blood fat, serum creatinine(Scr), blood urea nitrogen(BUN), serum uric acid(SUA), brain natriuretic peptide(BNP), interleukin-6(IL-6) and tumor necrosis factor-a(TNF-a) analysis before they had taken medicine and after8weeks’ treatment. At the same time, blood pressure, left ventricular ejection fraction(LVEF) and left ventricular internal dimension diastole(LVEDD) were measured.Results1. Compared with baseline, SBP and SUA in allopurinol group were significantly decreased(P<0.05). SUA in benzbromarone group was lower(P<0.05), but there were no significant difference in placebo group(all P>0.05). After8weeks’ treatment, compared with placebo group, SBP and SUA in allopurinol group were lower than placebo group (all P<0.05), but there was no obvious difference between placebo group and benzbromarone group(P>0.05).2. After8weeks’treatment, compared with baseline, the serum level of IL-6and TNF-a were obviously depressed in allopurinol group and benzbromarone group(all P<0.05); increased in placebo group(P<0.05). After8weeks’ treatment, compared with placebo group, IL-6and TNF-a in allopurinol group and benzbromarone group were obviously decreased (all P<0.05). But there were no significant difference in placebo group and benzbromarone group(all P>0.05).3. Compared with baseline, the level of BNP and LVEDD in allopurinol group were decreased, and LVEF was increased after8weeks’ treatment(all P<0.05); BNP were decreased in placebo group and benzbromarone group, but there were no significant difference of LVEDD, LVEF, BUN and Scr in placebo group and benzbromarone group(all P>0.05).After8weeks’ treatment, compared with placebo group, BNP and LVEDD were decreased, and LVEF was increased in allopurinol group(all P<0.05); but there were no obvious change of BNP, LVEDD, LVEF, BUN and Scr in benzbromarone group(all P>0.05).Conclusion1. Both allopu inol and benzbromarone can reduce serum uric acid level, and mitigate inflammatory response in patients with chronic heart failure and hyperuricemia.2. Allopurinol can lower systolic blood pressure, improve the situation of cardiac function in heart failure patients with hyperuricemia; But benzbromarone have no significant effect on systolic blood pressure and heart function.3. Short-term uric acid-lowering therapy had no obvious effect on renal function with allopurinol and benzbromarone.4. Allopurinol as Xanthine oxidase(XO) inhibitor can significantly improve cardiac function, and xanthine oxidase may be involved in the pathophysiology process and promote the further development of heart failure in patients with hyperuricemia.